+91-80-26860424 / 34

Call Us Today



Pharma patents Tag

BananaIP Counsels > Posts tagged "Pharma patents"

A Patently Generic Win

This post was first published on April 23, 2012. In a landmark decision on a generic drug-maker’s ability to introduce a generic drug for uses not indicated on the branded product’s label, the US Supreme Court ruled in favour of Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries, in its patent litigation against Novo Nordisk over Caraco’s generic version of Prandin, repaglinide tablets, a blood glucose lowering drug. The drug in question, Prandin, generically known as repaglinide, is used for treatment of Type-2 diabetes. The drug is approved for three different uses, out of which Novo had valid patent on one....

Continue reading

Restricting ‘Pay-for-Delay’ Agreements

This post was first published on 6th August, 2014.   A total of more than 420 million Euros was imposed recently as fine by the European Competition Commission on five major Pharma companies for entering into ‘Pay-for-delay’ agreements with Generic companies. These fines and related measures were imposed to restrict the drug majors from entering into these non-competitive kind of deals to maximize their commercial gains. Of the five, the drug maker, Servier has been fined 331 million Euros for the anti-hypertensive drug Coversyl (perindopril). The other companies included are Teva Pharmaceuticals, Lupin, Mylan, Krka and Unichem Laboratories. The restriction on the pay-for-delay...

Continue reading

Indian Patent Statistics, Interesting Inventions, WIPO – India Summer School, NATCO Pharma patent settlement and more

The featured image reads Weekly News Updates: Patent News. The logo of intellepedia also forms part of the featured image. To read more click here.

  “Indian Patent Statistics, Interesting Inventions, Industrial Designs Statistics, BananaIP completes 15 years, WIPO – India Summer School on IP to begin in June, NATCO Pharma settles infringement dispute with Onyx Therapeutics, South Korea to host this year’s IP5 roundtable and more patent news” presented by the Patent attorneys and experts of BananaIP Counsels, India’s leading Patent Firm. Quote of the Week  “Patent knowledge cannot promote scientific progress unless it is accessible.” - Dr. Kalyan C. Kankanala, BananaIP Counsels Indian Patent Statistics A total of 789 patent applications have been published in the 22nd issue of the Patent Journal, 2019. Out of the 789 applications...

Continue reading

Patent Suit over Viagra

This post was first published on June 7, 2011. Pfizer Inc. filed a suit against Watson Laboratories, on June 1, 2011 in the United States District Court for the Southern District of New York seeking to prevent Watson from commercializing sildenafil citrate tablets prior to the expiration of Pfizer’s Viagra. Watson's sildenafil citrate tablets are a generic version of Pfizer Inc.'s Viagra, which is indicated for the treatment of erectile dysfunction (ED). Sildenafil citrate enhances the effect of nitric oxide, which plays a key role in creating erections, by inhibiting a chemical which can restrict its action. Pfizer's lawsuit was filed...

Continue reading

Generication of Public Interest

This post was first published on 18th February, 2011. Public Interest today is a potent weapon of generic companies to safeguard their interests in the changing patent landscape in India. India's membership to WTO required implementation of the product patent regime for drugs by 2005 and implementation of the obligation was opposed by generic companies in the name of public interest. It was argued that the introduction of such a regime would impede access to medicines and health care. The public consciousness and media's highlighting of the importance of access to AIDS and cancer drugs pushed the contention of Innovator companies...

Continue reading

Abbott’s HIV Drug Patent “Not an Invention”

This post was first published on 18th January, 2011. In a recent case, reported here by Sandeep, the patent office denied patent grant to Abbott’s HIV drug application (application No:339/MUMNP/2006, WO2005/039551), stating that the subject matter did not constitute an invention. Abbott’s application was rejected as a result of the pre grant oppositions filed by Initiative for Medicines, Access & Knowledge’ (I-MAK), Cipla (Mumbai), Matrix Laboratories (Secunderabad) and Okasa Pharmaceuticals (Mumbai). The complete specification of Abbott’s application was entitled “SOLID PHARMACEUTICAL DOSAGE FORM” and had the  conventional priority of US application No. 10/650,178 dated 28th  August, 2003. The complete specification had 37...

Continue reading

Patent Law News Update

The featured image reads Weekly News Updates: Patent News. The logo of intellepedia also forms part of the featured image. To read more click here.

  Interesting Patents, Amazon’s parachute-dropping drone, Facebook - electronic payment service, Recent Patent Grants, Glenmark obtains US FDA approval, Pharma Patents, Whirlpool Patent Infringement, Stupid Designs, Patent Search, Patent Tip and more, presented by the Patent attorneys and experts of BananaIP Counsels, India’s Premier New Age IP Firm. Patent Quote of the week “Abraham Lincoln said, Patents Add Fuel to the Fire of Genius. What the great man did not say is that Too Much Fuel Can Burn the Genius” ― Dr. Kalyan C. Kankanala, Renowned IP Attorney, Professor and Novelist Patent stats from the Indian Patent Office While there has been a slight decrease of 16.05% in the sum...

Continue reading

‘Affordability, Availability, Accessibility of medicines’

The image is of medicines as the post is about pharma patents and access to medicines and a conference held on the topic. To read click here.

The Centre for Intellectual Property Rights Research and Advocacy, headed by Professor T. Ramakrishna (Chair professor of IP at NLSIU),  and the MHRD Chair on IPR of National Law School of India University, Bangalore in association with the National Pharmaceutical Pricing Authority, New Delhi organized a one day national conference on ‘Affordability, Availability, Accessibility of medicines and IPR’ on the 5th of January 2016. The main objective of the conference was to provide a platform to the government representatives, stakeholders and general public to discuss on issues including the challenges and opportunities of the National Pharmaceutical Pricing policy, Business policies of...

Continue reading

Pharma Patents and Drug Prices- A Presentation by Dr. Kalyan C. Kankanala at NLSIU, Bangalore

The image says Pharma Patents and Drug Prices, as the post contains a presentation on the same. Click to read more.

The following presentation titled ‘Pharma Patents and Drug Prices’ was delivered by Dr. Kalyan C. Kankanala (Managing Partner, BananaIP Counsels, Bangalore) on 5th January, 2016 at the conference on “Affordability, Accessibility and Availability of Medicine and IPR” at National Law School of India University. Organized through the Centre for Intellectual Property Rights Research and Advocacy and MHRD Chair on Intellectual Property Rights, the conference was held at the International Training Centre, NLSIU, Bengaluru. The following topics were covered as a part of the presentation- Patents and pricing Patentability/ Enforceability- Imatinib case, Sitagliptin case Patent Decision Predictability Quadrant (Patent Holder’s Perspective) With the...

Continue reading

World’s Best IP Blogs: Patent Baristas

For most people, an ideal day begins with a cup of coffee and a newspaper. The blog that we bring to you today is rather unique in its concept and content. It gives you the exact feel of sipping coffee while updating yourself with the latest IP news. Often featured as one of the top pharma blogs, Patent Baristas serves its readers with some “patent chat over a steaming cup of Coffee.”  Patent Baristas is an intellectual property news and commentary weblog which features fresh news on patent and IP issues, particularly in the field of biosciences. Stephen Jenei, the founder...

Continue reading
Speak with an IP Expert Today
close slider